Article info

Download PDFPDF

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Authors

  • Fanny Ledys Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France Université de Bourgogne-Franche comté, Faculté des Sciences de Santé Dijon France PubMed articlesGoogle scholar articles
  • Quentin Klopfenstein Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France PubMed articlesGoogle scholar articles
  • Caroline Truntzer Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France PubMed articlesGoogle scholar articles
  • Laurent Arnould Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France Department of PathologyCentre Georges-François Leclerc Dijon France PubMed articlesGoogle scholar articles
  • Julie Vincent Department of Medical Oncology, Centre Georges-François Leclerc Dijon France PubMed articlesGoogle scholar articles
  • Leila Bengrine Department of Medical Oncology, Centre Georges-François Leclerc Dijon France PubMed articlesGoogle scholar articles
  • Romain Remark Innate Pharma 117 Avenue de Luminy Marseille France PubMed articlesGoogle scholar articles
  • Romain Boidot Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France GIMI Genetic and Immunology Medical Institute Dijon France PubMed articlesGoogle scholar articles
  • Sylvain Ladoire Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France Université de Bourgogne-Franche comté, Faculté des Sciences de Santé Dijon France Department of Medical Oncology, Centre Georges-François Leclerc Dijon France INSERM UMR1231 Dijon France PubMed articlesGoogle scholar articles
  • Francois Ghiringhelli Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France Université de Bourgogne-Franche comté, Faculté des Sciences de Santé Dijon France GIMI Genetic and Immunology Medical Institute Dijon France Department of Medical Oncology, Centre Georges-François Leclerc Dijon France INSERM UMR1231 Dijon France PubMed articlesGoogle scholar articles
  • Valentin Derangere Cancer Biology Research Platform, Centre Georges-François Leclerc Dijon France Université de Bourgogne-Franche comté, Faculté des Sciences de Santé Dijon France GIMI Genetic and Immunology Medical Institute Dijon France PubMed articlesGoogle scholar articles
  1. a fledys{at}cgfl.fr
  2. b qklopfenstein{at}cgfl.fr
  3. c ctruntzer{at}cgfl.fr
  4. d larnould{at}cgfl.fr
  5. e jvincent{at}cgfl.fr
  6. f lbengrine{at}cgfl.fr
  7. g romain.remark{at}innate-pharma.fr
  8. h rboidot{at}cgfl.fr
  9. i sladoire{at}cgfl.fr
  10. j (33) 3-80-39-33-53 fghiringhelli{at}cgfl.fr
  11. k (33) 3-80-39-33-53 vderangere{at}cgfl.fr
View Full Text

Citation

Ledys F, Klopfenstein Q, Truntzer C, et al
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Publication history

  • Received August 1, 2018
  • Accepted October 31, 2018
  • First published November 19, 2018.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.